{"entity":{"id":"huabo-biopharm","kind":"company","name":"Huabo Biopharm","aka":["Shanghai Huaota Biopharmaceutical","Huaota Biopharm","华奥泰生物"],"tldr":"Huabo Biopharm is a Shanghai antibody company whose bispecific HB0036 blocks PD-L1 and TIGIT at once so that exhausted T cells can attack the tumour.","summary":"Huabo Biopharm (Shanghai Huaota Biopharmaceutical) is a Shanghai-based developer of monoclonal and bispecific antibodies. Its oncology pipeline includes HB0036, a bispecific antibody against PD-L1 and TIGIT that is in phase 1/2 trials in advanced solid tumours including non-small cell lung cancer, alongside HB0025 (PD-L1 and VEGF) and HB0017, an IL-17A antibody for psoriasis.","asOf":"2026-09-17","links":[],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["hb0036"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Shanghai","country":"CN","companyType":"biotech","investors":[],"funding":[]},"route":"/companies/huabo-biopharm/","neighbours":{"drug":[{"id":"hb0036","kind":"drug","name":"HB0036","route":"/drugs/hb0036/"}]}}